What were the results of the PIONEER AF study?
The rates of clinically significant bleeding were lower in the 2 groups receiving rivaroxaban than in the VKA group (16.8% in group 1, 18.0% in group 2, and 26.7% in group 3; HR for group 1 group 2 vs group 3, 0.63; 95% CI, 0.50-0.80; P < .001). The rates of death from cardiovascular causes, MI, or stroke were similar in the 3 groups, but the trial was underpowered for efficacy end points. There was only a minority of newer P2Y12 inhibitors used as APT.